Keros Therapeutics (NASDAQ:KROS) Director Alpna Seth Sells 2,625 Shares

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Alpna Seth sold 2,625 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the sale, the director directly owned 9,767 shares of the company’s stock, valued at approximately $104,702.24. This represents a 21.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Price Performance

Shares of KROS opened at $10.30 on Friday. The firm has a market cap of $203.84 million, a P/E ratio of -3.42 and a beta of 0.94. The stock has a 50 day simple moving average of $11.33 and a two-hundred day simple moving average of $15.17. Keros Therapeutics, Inc. has a 1 year low of $9.79 and a 1 year high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The firm had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. On average, equities analysts anticipate that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on KROS. Wells Fargo & Company cut their target price on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Weiss Ratings lowered Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Finally, Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $20.40.

Institutional Trading of Keros Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Keros Therapeutics by 3.3% during the third quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock valued at $43,011,000 after purchasing an additional 87,129 shares during the period. Western Standard LLC boosted its stake in shares of Keros Therapeutics by 42.7% during the third quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock valued at $34,644,000 after purchasing an additional 654,989 shares during the period. Jacobs Levy Equity Management Inc. boosted its stake in shares of Keros Therapeutics by 26.6% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company’s stock valued at $15,645,000 after purchasing an additional 161,336 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after purchasing an additional 205,022 shares during the period. Finally, Federated Hermes Inc. boosted its stake in shares of Keros Therapeutics by 27.3% during the fourth quarter. Federated Hermes Inc. now owns 654,724 shares of the company’s stock valued at $13,330,000 after purchasing an additional 140,564 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.